Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.
Advertisement
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Bristol-Myers Squibb won FDA approval for its novel schizophrenia drug, Cobenfy. BMY stock rose late, signaling a breakout Friday.